You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

PTCL (peripheral T-cell lymphoma)

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Trial (GFH009)

Not yet recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)
  • (no location specified)
Jun 28, 2023

Newly Diagnosed Peripheral T-cell Lymphoma Trial in Wuhan (Duvelisib, Chidamide)

Recruiting
  • Newly Diagnosed Peripheral T-cell Lymphoma
  • Duvelisib, Chidamide
  • Wuhan, Hubei, China
    Union Hospital, Tongji Medical College, Huazhong University of S
Jul 27, 2023

Peripheral T Cell Lymphoma Trial in Zhengzhou (Golidocitinib, CHOP Regimen)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • Zhengzhou, Henan, China
    Henan Cancer Hospital
Jul 18, 2023

Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Refractory T-Cell Lymphoma Trial in Xiamen (Chidamide combined

Recruiting
  • Peripheral T Cell Lymphoma
  • +2 more
  • Chidamide combined with Duvillisib
  • Xiamen, Fujian, China
    The First Affiliated Hosptial of Xiamen University
Nov 28, 2023

Peripheral T-cell Lymphoma Targeted Therapy Trial in Tianjin (Azacitidine, Chidamide, Cyclophosphamide)

Enrolling by invitation
  • Peripheral T-cell Lymphoma Targeted Therapy
  • Tianjin, Tianjin, China
    Tianjin Medical University Cancer Insititute & Hospital
Jan 9, 2023

Peripheral T Cell Lymphoma Trial (CHOP+selinexor+5-Azacitidine, CHOP+duvelisib+5-Azacitidine, CHOP+chidamide+tislelizumab)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • (no location specified)
Dec 29, 2022

Relapsed or Refractory Peripheral T-cell Lymphoma Trial in Taiwan (Chidamide)

Not yet recruiting
  • Relapsed or Refractory Peripheral T-cell Lymphoma
  • Kaohsiung, Taiwan
  • +4 more
Apr 17, 2023

Peripheral T Cell Lymphoma Trial in Shanghai (Azacitidine Injection, Dasatinib, Linperlisib)

Recruiting
  • Peripheral T Cell Lymphoma
  • Azacitidine Injection
  • +6 more
  • Shanghai, Shanghai, China
    Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
Nov 8, 2022

Peripheral T Cell Lymphoma Trial in Harlingen (Belinostat Injection, Pralatrexate Injection, CHOP)

Not yet recruiting
  • Peripheral T Cell Lymphoma
  • Belinostat Injection
  • +3 more
  • Harlingen, Texas
    Valley Cancer Associates
Oct 16, 2023

Allo-HSCT as First-line Consolidation in High-risk PTCL

Recruiting
  • T Cell Lymphoma
    • Beijing, China
      Peking University People's Hospital
    Jul 31, 2022

    Newly Diagnosed Peripheral T-cell Lymphoma Trial in Nanjing (C-BEAM Regimen, BEAM Regimen)

    Recruiting
    • Newly Diagnosed Peripheral T-cell Lymphoma
    • C-BEAM Regimen
    • BEAM Regimen
    • Nanjing, Jiangsu, China
      Hematological Department, People's Hospital of Jiangsu Province
    Jun 27, 2023

    Relapsed or Refractory Hodgkin Lymphoma, Peripheral T Cell Lymphoma Trial (AFM13, AB-101, Cyclophosphamide)

    Not yet recruiting
    • Relapsed or Refractory Hodgkin Lymphoma
    • Peripheral T Cell Lymphoma
    • (no location specified)
    May 30, 2023

    First-line Maintenance Treatment of PTCL With Chidamide.

    Recruiting
    • PTCL
    • Nanjing, Jiangsu, China
      Hematological Department, People's Hospital of Jiangsu Province
    Jul 23, 2023

    HRAS Mutations or Peripheral T Cell Lymphoma (PTCL) Trial (Tipifarnib)

    Available
    • HRAS Mutations or Peripheral T Cell Lymphoma (PTCL)
    • (no location specified)
    Jun 7, 2022

    Peripheral T-Cell Lymphoma (PTCL) Trial in Japan, Korea, Republic of (HBI-8000)

    Completed
    • Peripheral T-Cell Lymphoma (PTCL)
    • Akita, Japan
    • +22 more
    Jun 8, 2022

    Peripheral T/NK Cell Lymphoma (R/R PTCL) Trial (YY-20394)

    Recruiting
    • Peripheral T/NK Cell Lymphoma (R/R PTCL)
    • Houston, Texas
      MD Anderson Cancer Center
    Oct 19, 2022

    Relapsed/Refractory Peripheral T-cell Lymphoma Trial in Fairport (Tolinapant, Decitabine + Cedazuridine)

    Recruiting
    • Relapsed/Refractory Peripheral T-cell Lymphoma
    • Aurora, Colorado
    • +2 more
    Jan 3, 2023

    Treatment, Peripheral T-cell Lymphoma Trial in Beijing (liposomal mitoxantrone HCl, gemcitabine, dexamethasone, and cisplatin)

    Recruiting
    • Treatment
    • Peripheral T-cell Lymphoma
    • liposomal mitoxantrone hydrochloride, gemcitabine, dexamethasone, and cisplatin
    • Beijing, China
    • +4 more
    Jun 28, 2022

    T-Cell Lymphoma Relapsed, T-Cell Lymphoma Refractory Trial in Italy (Venetoclax)

    Active, not recruiting
    • T-Cell Lymphoma Relapsed
    • T-Cell Lymphoma Refractory
    • Aviano, Italy
    • +12 more
    Dec 20, 2022

    Refractory T-Cell Lymphoma, Relapsed T-Cell Lymphoma Trial in Italy (Daratumumab)

    Active, not recruiting
    • Refractory T-Cell Lymphoma
    • Relapsed T-Cell Lymphoma
    • Bari, Italy
    • +6 more
    Aug 1, 2022

    Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Follicular T-Cell

    Recruiting
    • Recurrent Angioimmunoblastic T-Cell Lymphoma
    • +13 more
    • Brentuximab Vedotin
    • Pembrolizumab
    • Chicago, Illinois
      Northwestern University
    Jun 15, 2022

    Peripheral T Cell Lymphoma Trial in Houston (Tenalisib)

    Withdrawn
    • Peripheral T Cell Lymphoma
    • Houston, Texas
      The University of Texas MD Anderson Cancer Center
    Oct 13, 2022

    Lymphoma Trial in China (Brentuximab Vedotin, Cyclophosphamide, Doxorubicin)

    Not yet recruiting
    • Lymphoma
    • Brentuximab Vedotin
    • +3 more
    • Beijing, China
    • +15 more
    Jan 4, 2023

    Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), Cutaneous T-Cell Lymphoma (CTCL) Trial in United States (KT-333)

    Recruiting
    • Non Hodgkin Lymphoma (NHL)
    • +4 more
    • Orange, California
    • +8 more
    Nov 29, 2022

    Mature T-Cell and NK-Cell Tumor Trial in Hwasun-gun (Copanlisib, Gemcitabine)

    Completed
    • Mature T-Cell and NK-Cell Neoplasm
    • Hwasun-gun, Jeollanam-do, Korea, Republic of
      Chonnam National University Hwasun Hospital
    Jun 9, 2022